Akero Therapeutics Inc

Akero Therapeutics Inc is a biotechnology firm focused on creating treatments for serious metabolic diseases, with a spotlight on metabolic dysfunction-associated steatohepatitis (MASH). Their leading product, efruxifermin, is advancing through Phase 3 clinical trials, aiming to regulate metabolism and protect against cellular stress. Originating as Pippin Pharmaceuticals and rebranded in 2018, Akero has partnered with Amgen Inc. for the development and distribution of its treatments. The company is based in South San Francisco, California, and was established in 2017.